265 related articles for article (PubMed ID: 25301077)
1. Plasma CX3CL1 levels and long term outcomes of patients with atrial fibrillation: the West Birmingham Atrial Fibrillation Project.
Guo Y; Apostalakis S; Blann AD; Lip GY
Cerebrovasc Dis; 2014; 38(3):204-11. PubMed ID: 25301077
[TBL] [Abstract][Full Text] [Related]
2. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
[TBL] [Abstract][Full Text] [Related]
3. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
4. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation.
Maehama T; Okura H; Imai K; Yamada R; Obase K; Saito K; Hayashida A; Neishi Y; Kawamoto T; Yoshida K
Am J Cardiol; 2010 Aug; 106(4):535-8. PubMed ID: 20691312
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
Krishnamoorthy S; Khoo CW; Lim HS; Lane DA; Pignatelli P; Basili S; Violi F; Lip GY
Eur J Clin Invest; 2013 Oct; 43(10):1032-8. PubMed ID: 23961715
[TBL] [Abstract][Full Text] [Related]
8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
[TBL] [Abstract][Full Text] [Related]
11. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
Roldán V; Marín F; García-Herola A; Lip GY
Thromb Res; 2005; 116(4):321-5. PubMed ID: 16038717
[TBL] [Abstract][Full Text] [Related]
12. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of the CHADS
Tabata N; Yamamoto E; Hokimoto S; Yamashita T; Sueta D; Takashio S; Arima Y; Izumiya Y; Kojima S; Kaikita K; Matsui K; Fujimoto K; Sakamoto K; Shimomura H; Tsunoda R; Hirose T; Nakamura N; Sakaino N; Nakamura S; Yamamoto N; Matsumura T; Kajiwara I; Koide S; Sakamoto T; Nakao K; Oshima S; Tsujita K;
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862941
[TBL] [Abstract][Full Text] [Related]
14. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
15. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
Ntaios G; Lip GY; Makaritsis K; Papavasileiou V; Vemmou A; Koroboki E; Savvari P; Manios E; Milionis H; Vemmos K
Neurology; 2013 Mar; 80(11):1009-17. PubMed ID: 23408865
[TBL] [Abstract][Full Text] [Related]
16. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
[TBL] [Abstract][Full Text] [Related]
17. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
[TBL] [Abstract][Full Text] [Related]
18. Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.
Su HM; Lin TH; Hsu PC; Lee WH; Chu CY; Lee CS; Voon WC; Lai WT; Sheu SH
Heart; 2013 Nov; 99(21):1588-96. PubMed ID: 24014280
[TBL] [Abstract][Full Text] [Related]
19. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
[TBL] [Abstract][Full Text] [Related]
20. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
